Novartis Pharmaceuticals Corporation restructuring US field force
New organizational alignment creates leaner, more flexible and productive organization
Novartis Pharmaceuticals Corporation (NPC) announced that it is restructuring its General Medicines field force in the US to reflect changes in the product portfolio and align resources with strategic growth priorities. The company will reduce its General Medicines field force by approximately 1,400 positions. These changes will be effective January 1, 2011.
The product portfolio within the NPC General Medicines business is changing due to pending patent expirations and pipeline products. There are new product launches expected within the Primary Care business and significant growth momentum within the Specialty Care business that will drive long-term success. Given these changing dynamics within the portfolio, it is critical to realign the General Medicines field force to sharpen focus on the greatest opportunities for growth. The restructuring is expected to result in a one-time cost of approximately $85 million.
"NPC has a robust pipeline and the future growth potential for our organization remains strong. Proactively evolving our business model will enable us to focus our resources on key launch products and capture opportunities in both primary care and specialty medicines," said Andy Wyss, Head of Novartis Pharma North America and President of Novartis Pharmaceuticals Corporation.
All reductions will be handled in a manner consistent with the Novartis commitment to fair and respectful treatment of associates. Outplacement and other support services will be available to impacted associates as well as redeployment opportunities, where they exist, within the Novartis Group of companies.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Birt-Hogg-Dubé_syndrome
Electronic Nose Sniffs Out Prostate Cancer
Category:Non-steroidal_anti-inflammatory_drugs
Epigenomics AG: New Clinical Data for Septin9 Colorectal Cancer Blood Test - Independent validation of laboratory test used in PRESEPT Study shows that the test finds 86% of the cancers

Survival specialists on Mount Everest - Humans are leaving behind a ‘frozen signature’ of hardy microbes
Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging

When mothers shut down the fathers’ genes in the embryo - “With our work, we were able to highlight a unique aspect of biology, a slice of nature’s broad diversity”

Bacterial soundtracks revealed by graphene membrane - Have you ever wondered if bacteria make distinctive sounds?
Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops

New target for Alzheimer's therapies found - Researchers discover link between the protein medin and Alzheimer's disease

Bioluminescence - the natural glow - How glowing molecules can also be used in industry
